Evaluation of bone metastases in lung cancer

Cancer Control

Volumn 9, Issue 3, 2002, Pages

  Malbotra, Poonam ^a   Berman, Claudia G ^a  

^a H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGED; ARTICLE; BONE METASTASIS; BONE SCINTISCANNING; CANCER STAGING; CASE REPORT; DIAGNOSTIC ACCURACY; FEMALE; HUMAN; LUNG CANCER; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; RADIODIAGNOSIS;

EID: 0036083633     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480200900311     Document Type: Article

References (10)

1. What does positron emission tomography offer oncology?
2. The role of positron emission tomography in the management of bone metastases
3. Detection of bone metastases in breast cancer by 18-FDG: Differing metabolic activity in osteoblastic and osteolytic lesions
4. Metastatic prostate cancer: Initial findings of PET with 2-deoxy-2-[F-18] fluoro-D-glucose
5. FDG PET can replace bone scintigraphy in primary staging of malignant lymphoma
6. Comparison and discrepancy of 18F-2-deoxyglucose positron emission tomography and Tc-99m MDP bone scan to detect bone metastases
7. Fluorine-18 deoxyglucose positron emission tomography for the detection of bone metastases in patients with non-small cell lung cancer
8. Diagnostic usefulness of F-18 FDG whole body PET in detection of bony metastases compared to TC-99m MDP bone scan
9. Staging techniques for lung cancer